CBUS
Price
$1.55
Change
+$0.04 (+2.65%)
Updated
Jul 3 closing price
Capitalization
75M
NWBO
Price
$0.25
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
362.31M
Interact to see
Advertisement

CBUS vs NWBO

Header iconCBUS vs NWBO Comparison
Open Charts CBUS vs NWBOBanner chart's image
Cibus
Price$1.55
Change+$0.04 (+2.65%)
Volume$214.07K
Capitalization75M
Northwest Biotherapeutics
Price$0.25
Change-$0.00 (-0.00%)
Volume$1.33M
Capitalization362.31M
CBUS vs NWBO Comparison Chart in %
Loading...
CBUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NWBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CBUS vs. NWBO commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CBUS is a Hold and NWBO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (CBUS: $1.55 vs. NWBO: $0.25)
Brand notoriety: CBUS and NWBO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CBUS: 43% vs. NWBO: 56%
Market capitalization -- CBUS: $75M vs. NWBO: $362.31M
CBUS [@Biotechnology] is valued at $75M. NWBO’s [@Biotechnology] market capitalization is $362.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CBUS’s FA Score shows that 1 FA rating(s) are green whileNWBO’s FA Score has 0 green FA rating(s).

  • CBUS’s FA Score: 1 green, 4 red.
  • NWBO’s FA Score: 0 green, 5 red.
According to our system of comparison, both CBUS and NWBO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CBUS’s TA Score shows that 6 TA indicator(s) are bullish while NWBO’s TA Score has 5 bullish TA indicator(s).

  • CBUS’s TA Score: 6 bullish, 4 bearish.
  • NWBO’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, CBUS is a better buy in the short-term than NWBO.

Price Growth

CBUS (@Biotechnology) experienced а +0.65% price change this week, while NWBO (@Biotechnology) price change was -0.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NWBO($362M) has a higher market cap than CBUS($75M). NWBO YTD gains are higher at: -9.554 vs. CBUS (-44.245). NWBO has higher annual earnings (EBITDA): -74.92M vs. CBUS (-264.18M). CBUS has more cash in the bank: 23.6M vs. NWBO (2.78M). CBUS has less debt than NWBO: CBUS (35.6M) vs NWBO (69M). CBUS has higher revenues than NWBO: CBUS (4.75M) vs NWBO (1.47M).
CBUSNWBOCBUS / NWBO
Capitalization75M362M21%
EBITDA-264.18M-74.92M353%
Gain YTD-44.245-9.554463%
P/E RatioN/AN/A-
Revenue4.75M1.47M323%
Total Cash23.6M2.78M849%
Total Debt35.6M69M52%
FUNDAMENTALS RATINGS
CBUS vs NWBO: Fundamental Ratings
CBUS
NWBO
OUTLOOK RATING
1..100
5057
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
6662
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CBUS's Valuation (21) in the null industry is in the same range as NWBO (36) in the Biotechnology industry. This means that CBUS’s stock grew similarly to NWBO’s over the last 12 months.

CBUS's Profit vs Risk Rating (100) in the null industry is in the same range as NWBO (100) in the Biotechnology industry. This means that CBUS’s stock grew similarly to NWBO’s over the last 12 months.

CBUS's SMR Rating (99) in the null industry is in the same range as NWBO (100) in the Biotechnology industry. This means that CBUS’s stock grew similarly to NWBO’s over the last 12 months.

NWBO's Price Growth Rating (62) in the Biotechnology industry is in the same range as CBUS (66) in the null industry. This means that NWBO’s stock grew similarly to CBUS’s over the last 12 months.

NWBO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CBUS (100) in the null industry. This means that NWBO’s stock grew similarly to CBUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CBUSNWBO
RSI
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CBUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NWBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ILGJX23.130.28
+1.23%
Columbia Integrated Large Cap Gr Ins 3
WLGRX34.760.35
+1.02%
Macquarie Large Cap Growth Fund R
SAMKX38.460.31
+0.81%
SA US Core Market
RGECX10.620.06
+0.57%
Russell Inv Global Equity C
SHDIX10.080.05
+0.50%
American Beacon Shapiro SMID Cap Eq R5

CBUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CBUS has been loosely correlated with ARCT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CBUS jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CBUS
1D Price
Change %
CBUS100%
+2.65%
ARCT - CBUS
41%
Loosely correlated
+1.17%
ABOS - CBUS
40%
Loosely correlated
+2.65%
CRBU - CBUS
38%
Loosely correlated
N/A
CGEM - CBUS
37%
Loosely correlated
+0.64%
FHTX - CBUS
36%
Loosely correlated
+3.64%
More

NWBO and

Correlation & Price change

A.I.dvisor tells us that NWBO and CCCC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NWBO and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NWBO
1D Price
Change %
NWBO100%
+0.85%
CCCC - NWBO
24%
Poorly correlated
-2.63%
CBUS - NWBO
23%
Poorly correlated
+2.65%
XERS - NWBO
23%
Poorly correlated
N/A
GLUE - NWBO
22%
Poorly correlated
+2.96%
VRTX - NWBO
21%
Poorly correlated
+0.57%
More